<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870972</url>
  </required_header>
  <id_info>
    <org_study_id>BCX7353-203</org_study_id>
    <nct_id>NCT02870972</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema</brief_title>
  <acronym>APeX-1</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BCX7353 as a Preventative Treatment to Reduce the Frequency of Attacks in Subjects With Hereditary Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 3-part study will evaluate the safety and efficacy of an oral treatment, BCX7353, in
      preventing angioedema attacks in subjects with hereditary angioedema (HAE). In Part 1 of the
      study, eligible subjects will be randomized to receive oral BCX7353 or placebo for 4 weeks.
      Assuming successful completion of Part 1, additional subjects will be randomized in Part 2 to
      one of 2 lower doses of BCX7353 or placebo. Part 3 will enroll additional subjects into one
      of three doses of BCX7353 or placebo. The study will compare the number of acute attacks in
      each treatment group, as well as a number of other clinical and pharmacologic outcomes, and
      the safety and tolerability of each dose of BCX7353 compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of confirmed HAE attacks</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events and laboratory abnormalities</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, as measured by the Angioedema Quality of Life Questionnaire</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, as measured by the Depression, Anxiety, Stress Scales (DASS) questionnaire</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of BCX7353 at steady state</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Hereditary Angioedema (HAE)</condition>
  <arm_group>
    <arm_group_label>Part 1: BCX7353 350 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCX7353 capsules, 350 mg dose administered once per day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parts 2 and 3: BCX7353 250 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCX7353 capsules, 250 mg dose administered once per day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parts 2 and 3: BCX7353 125 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCX7353 capsules, 125 mg dose administered once per day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parts 1, 2 and 3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules, administered once per day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: BCX7353 62.5 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCX7353 capsules, 62.5 mg dose administered once per day for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCX7353</intervention_name>
    <description>Plasma kallikrein inhibitor</description>
    <arm_group_label>Part 1: BCX7353 350 mg once daily</arm_group_label>
    <arm_group_label>Parts 2 and 3: BCX7353 250 mg once daily</arm_group_label>
    <arm_group_label>Parts 2 and 3: BCX7353 125 mg once daily</arm_group_label>
    <arm_group_label>Part 3: BCX7353 62.5 mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Parts 1, 2 and 3: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  A clinical diagnosis of HAE type I or II

          -  Documented HAE attacks within a defined calendar period

          -  Access to acute attack medications

          -  Sexually active women of child-bearing potential and sexually active men must utilize
             effective contraception

        Key Exclusion Criteria:

          -  Women who are pregnant or breast-feeding

          -  Any clinical condition or medical history that would interfere with the subject's
             safety or ability to participate in the study

          -  Use of C1INH, androgens or tranexamic acid for prophylaxis of HAE attacks

          -  History of or current alcohol or drug abuse

          -  Infection with hepatitis B, hepatitis C or HIV

          -  Participation in any other investigational drug study currently or within the last 30
             days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emel Aygören-Pürsün, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Frankfurt Goethe University</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campbelltown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skopje</city>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brimingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

